NCCN clinical practice guidelines recommend PD-1/PD-L1 inhibitors (Pembrolizumab, Nivolumab and Avelumab) as an option for the treatment of GTN resistant to chemotherapy [8]. The gene discussed is CD274; the disease is gestational trophoblastic neoplasm.